+ Watch AUXL
on My Watchlist
A specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians.
Do any investors out there know anything about Dupuytren's contracture? It is not very common. Most patients who need intervention would be referred to an orthopedic surgeon. If Xiaflex were actually FDA approved, the surgeon could recommend either fixing the problem surgically or trying injections of a new agent that would require multiple visits and doesn't always work. With regard to insurance company payment, with surgery, they pay a physician fee for the operation and a hospital fee for the procedure. With Xiaflex, they would pay Auxilium for the drug, the physician fee for the procedure (injection), and the hospital/clinic fee for the procedure. If the drug is priced too high or it requires multiple visits for repeat injections, the companies will not approve payment for xiaflex, and the patient will be left only with the option of surgery. If the drug is priced lower and insurance will pay for it, the surgeon will consider his physician fee for operation (high) or injection (low). Most surgeons are already biased toward performing surgery, and the financial disadvantage for choosing injection rather than operation will influence most surgeons to continue with the established standard of care which is surgery.
Wrong! I am an orthopaedic hand surgeon. Dupuytren's Disease is very common. I see at least 2 new patients every week for the condition. Surgical management of the condition will often include hand therapy for 6-12 weeks. Full correction is unusual and complications are not uncommon. The cost to the insurance carrier is substantial. If I am provided with a comparable non-operative technique that has fewer complications and an easier recovery for the patient at a comparable cost, I will choose it. The surgical reimbursement is poor and I would love to have a non-operative procedure that I can do in the office without wasting time in the operating room. I am more efficient and profitable in my office versus the operating room.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions